Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gold Fields Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Gold Fields Limited trades at $39.77 (market cap $36.07B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays a 5.76% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GFI | |
|---|---|---|
Market Cap | $29.60B | $36.07B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $61.52 |
52-Week Low | $205.48 | $29.31 |
Enterprise Value | $27.56B | $37.51B |
Dividend Yield | — | 5.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Gold Fields (GFI) trades at $41.06, down slightly by 0.15% today. The stock shows strong fundamentals with robust profitability (40.76% net margin, 52.33% ROE) and attractive valuation (P/E 10.22, EV/EBITDA 5.92). Recent earnings were mixed with one beat and two misses, but 2025 projections indicate significant growth. Technical indicators show a bullish overall signal despite overbought RSI readings. Institutional interest remains strong with recent acquisitions by major funds.
The outlook for GFI appears positive with projected revenue growth to $8.8B and net income of $3.6B in 2025. Analyst consensus targets $52.00 (24% upside) with no sell ratings. Key risks include gold price volatility and operational challenges in mining operations. The combination of strong fundamentals, institutional support, and growth projections supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
